We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Simulations Plus (SLP) Restructures Business Unit Post-Acquisitions
Read MoreHide Full Article
Simulations Plus, Inc. (SLP - Free Report) has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024.
Over the past year, Simulations Plus made two major acquisitions, including the largest in its corporate history. In June 2024, the company acquired Pro-ficiency Holdings, Inc. and its subsidiaries from QHP Capital and its minority shareholders for about $100 million, expanding its footprint across the drug development continuum, from pre-clinical protocols to product commercialization. This acquisition doubled Simulations Plus’ addressable market by adding $4 billion in revenue opportunities within the clinical simulations training, analytics and medical communications sectors.
Building on this recent acquisition, Simulations Plus is focusing on optimizing its resources and people. The company is establishing two new business units — Adaptive Learning & Insights and Medical Communications — to improve client engagement. Additionally, the Regulatory Strategies unit will transition into a Regulatory Strategies Center of Excellence to enhance sales visibility and accelerate cross-selling opportunities.
These strategic moves aim to strengthen Simulations Plus’ position across the drug development continuum, driving growth and profitability, the company added.
Simulations Plus announced key leadership promotions. Steven Chang is elevated to president of Quantitative Systems Pharmacology following his arrival with the Immunetrics acquisition in June 2023. Jenna Rouse will lead the new Adaptive Learning & Insights unit as president, having served as chief markets officer, Clinical, at Pro-ficiency. Murry Alper will become president of the new Medical Communications unit, also joining through the Pro-ficiency acquisition.
The company further announced the departure of Brett Howell, president of Quantitative Systems Pharmacology, and Michael Raymer, president of Clinical Simulations & Medical Communications, who will leave after aiding in the transition.
Simulations Plus is a leading-edge developer of simulation software for pharmaceutical, chemical and biotechnology companies across the globe. The simulation software is used for drug discovery, development, research and regulatory submissions.
In the third quarter of fiscal 2024, the company’s revenues increased 14% year over year to $18.5 million, primarily due to higher software revenues in the Clinical Pharmacology & Pharmacometrics and Cheminformatics business units.
However, sales of the PBPK unit, part of the services segment, were down 10% as the temporary delays in acquiring client source data deferred the initiation of contracted projects. SLP has also opted to discontinue the quarterly cash dividend and redirect these funds towards growth initiatives to boost long-term shareholder value.
Currently, Simulations Plus carries a Zacks Rank #4 (Sell). Shares of the company have lost 19.4% compared with the sub-industry’s growth of 24.7%.
Image Source: Zacks Investment Research
Stocks to Consider
Manhattan Associates, Inc. (MANH - Free Report) , sporting a Zacks Rank #1 (Strong Buy) at present, has delivered an earnings surprise of 26.6%, on average, in the trailing four quarters. In the last reported quarter, MANH delivered an earnings surprise of 22.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANSYS, Inc. (ANSS - Free Report) , carrying a Zacks Rank #2 (Buy) at present, has delivered an earnings surprise of 4.8%, on average, in three of the trailing four quarters. In the last reported quarter, ANSS delivered an earnings surprise of 28.9%. It has a long-term earnings growth expectation of 6.4%.
Adobe Inc. (ADBE - Free Report) , carrying a Zacks Rank #2 at present, has delivered an earnings surprise of 2.7%, on average, in the trailing four quarters. In the last reported quarter, ADBE delivered an earnings surprise of 2.1%. It has a long-term earnings growth expectation of 13%.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Simulations Plus (SLP) Restructures Business Unit Post-Acquisitions
Simulations Plus, Inc. (SLP - Free Report) has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024.
Over the past year, Simulations Plus made two major acquisitions, including the largest in its corporate history. In June 2024, the company acquired Pro-ficiency Holdings, Inc. and its subsidiaries from QHP Capital and its minority shareholders for about $100 million, expanding its footprint across the drug development continuum, from pre-clinical protocols to product commercialization. This acquisition doubled Simulations Plus’ addressable market by adding $4 billion in revenue opportunities within the clinical simulations training, analytics and medical communications sectors.
Building on this recent acquisition, Simulations Plus is focusing on optimizing its resources and people. The company is establishing two new business units — Adaptive Learning & Insights and Medical Communications — to improve client engagement. Additionally, the Regulatory Strategies unit will transition into a Regulatory Strategies Center of Excellence to enhance sales visibility and accelerate cross-selling opportunities.
These strategic moves aim to strengthen Simulations Plus’ position across the drug development continuum, driving growth and profitability, the company added.
Simulations Plus announced key leadership promotions. Steven Chang is elevated to president of Quantitative Systems Pharmacology following his arrival with the Immunetrics acquisition in June 2023. Jenna Rouse will lead the new Adaptive Learning & Insights unit as president, having served as chief markets officer, Clinical, at Pro-ficiency. Murry Alper will become president of the new Medical Communications unit, also joining through the Pro-ficiency acquisition.
Simulations Plus, Inc. Price and Consensus
Simulations Plus, Inc. price-consensus-chart | Simulations Plus, Inc. Quote
The company further announced the departure of Brett Howell, president of Quantitative Systems Pharmacology, and Michael Raymer, president of Clinical Simulations & Medical Communications, who will leave after aiding in the transition.
Simulations Plus is a leading-edge developer of simulation software for pharmaceutical, chemical and biotechnology companies across the globe. The simulation software is used for drug discovery, development, research and regulatory submissions.
In the third quarter of fiscal 2024, the company’s revenues increased 14% year over year to $18.5 million, primarily due to higher software revenues in the Clinical Pharmacology & Pharmacometrics and Cheminformatics business units.
However, sales of the PBPK unit, part of the services segment, were down 10% as the temporary delays in acquiring client source data deferred the initiation of contracted projects. SLP has also opted to discontinue the quarterly cash dividend and redirect these funds towards growth initiatives to boost long-term shareholder value.
Currently, Simulations Plus carries a Zacks Rank #4 (Sell). Shares of the company have lost 19.4% compared with the sub-industry’s growth of 24.7%.
Image Source: Zacks Investment Research
Stocks to Consider
Manhattan Associates, Inc. (MANH - Free Report) , sporting a Zacks Rank #1 (Strong Buy) at present, has delivered an earnings surprise of 26.6%, on average, in the trailing four quarters. In the last reported quarter, MANH delivered an earnings surprise of 22.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANSYS, Inc. (ANSS - Free Report) , carrying a Zacks Rank #2 (Buy) at present, has delivered an earnings surprise of 4.8%, on average, in three of the trailing four quarters. In the last reported quarter, ANSS delivered an earnings surprise of 28.9%. It has a long-term earnings growth expectation of 6.4%.
Adobe Inc. (ADBE - Free Report) , carrying a Zacks Rank #2 at present, has delivered an earnings surprise of 2.7%, on average, in the trailing four quarters. In the last reported quarter, ADBE delivered an earnings surprise of 2.1%. It has a long-term earnings growth expectation of 13%.